Breaking News Instant updates and real-time market news.

DERM

Dermira

$33.82

1.15 (3.52%)

04:48
10/03/16
10/03
04:48
10/03/16
04:48

Dermira says CIMPASI-2 trial met co-primary efficacy endpoints

UCB and Dermira announced topline results from CIMPASI-2, a Phase 3, multi-center, placebo-controlled clinical trial evaluating the efficacy and safety of CIMZIA in adult patients with moderate-to-severe chronic plaque psoriasis. In the CIMPASI-2 trial, CIMZIA demonstrated statistically significant improvements for both co-primary endpoints compared to placebo at both treatment doses. The CIMPASI-2 trial results are from the first of three Phase 3 clinical trials to be reported evaluating CIMZIA in this patient population. The co-primary endpoints evaluated in the trial were the percentage of patients who achieved a 75% or greater disease improvement from baseline as measured by the Psoriasis Area and Severity Index and the percentage of patients achieving at least a two-point improvement on a five-point Physician's Global Assessment scale to a final score representing clear or almost clear skin, each compared with placebo, at week 16.

DERM Dermira
$33.82

1.15 (3.52%)

05/10/16
LEER
05/10/16
NO CHANGE
Target $46
LEER
Outperform
Dermira price target raised to $46 from $39 at Leerink
05/10/16
LEER
05/10/16
NO CHANGE
Target $46
LEER
Outperform
Dermira price target raised to $46 from $39 at Leerink
Leerink analyst Seamus Fernandez raised his price target for Dermira to $46 after upping his probability-of-success for DRM01, a topical sebum inhibitor for acne, to 90% from 75%. Top-line data showed "strongly positive" Phase IIb dose-ranging efficacy and safety, Fernandez tells investors in a post-earnings research note. He points out Dermira plans to advance DRM01 into Phase III in the first half of 2017. The analyst keeps an Outperform rating on the shares.
06/02/16
LEER
06/02/16
NO CHANGE
Target $47
LEER
Outperform
Dermira DRM04 results 'broadly positive,' says Leerink
Following top-line data from the two Phase 3 studies of Dermira's DRM04 for the treatment of hyperhidrosis, Leerink analyst Seamus Fernandez is raising his overall probability of success from 75% to 85%. The analyst sees the new data as "broadly positive," and notes that Dermira remains one of his Small-/Mid-Cap Top-Picks for 2016. Fernandez reiterates an Outperform rating on the stock and raised his price target on the shares to $47 from $46.
09/09/16
LEER
09/09/16
NO CHANGE
LEER
Leerink updates therapeutics best ideas for 2016
In a note to investors this morning, Leerink has updated its best ideas for 2016 from the firm's five therapeutics analysts. The list includes Alexion (ALXN), Dermira (DERM), Intra-Cellular (ITCI), Sanofi (SNY), Allergan (AGN), Alnylam (ALNY), Innate Pharma (IPHYF), The Medicines Co. (MDCO), and Ophthotech (OPHT).

TODAY'S FREE FLY STORIES

INN

Summit Hotel Properties

$15.46

0.1 (0.65%)

05:20
09/26/17
09/26
05:20
09/26/17
05:20
Upgrade
Summit Hotel Properties rating change  »

Summit Hotel Properties…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

DRE

Duke Realty

$29.28

0.17 (0.58%)

05:17
09/26/17
09/26
05:17
09/26/17
05:17
Downgrade
Duke Realty rating change  »

Duke Realty downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REXR

Rexford Industrial

$29.56

0.05 (0.17%)

05:15
09/26/17
09/26
05:15
09/26/17
05:15
Downgrade
Rexford Industrial rating change  »

Rexford Industrial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCO

Taubman Centers

$50.00

0.86 (1.75%)

05:14
09/26/17
09/26
05:14
09/26/17
05:14
Downgrade
Taubman Centers rating change  »

Taubman Centers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Oct

  • 11

    Oct

KIM

Kimco Realty

$19.58

0.4 (2.09%)

05:11
09/26/17
09/26
05:11
09/26/17
05:11
Upgrade
Kimco Realty rating change  »

Kimco Realty upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

GGP

GGP

$20.75

0.25 (1.22%)

05:11
09/26/17
09/26
05:11
09/26/17
05:11
Upgrade
GGP rating change  »

GGP upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAC

Macerich

$54.16

1.44 (2.73%)

05:10
09/26/17
09/26
05:10
09/26/17
05:10
Upgrade
Macerich rating change  »

Macerich upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DY

Dycom

$81.23

-1.46 (-1.77%)

05:06
09/26/17
09/26
05:06
09/26/17
05:06
Initiation
Dycom initiated  »

Dycom initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

PNC

PNC Financial

$133.52

0.09 (0.07%)

, GS

Goldman Sachs

$230.26

-0.77 (-0.33%)

05:04
09/26/17
09/26
05:04
09/26/17
05:04
Downgrade
PNC Financial, Goldman Sachs, Wells Fargo, Morgan Stanley, JPMorgan rating change  »

PNC Financial downgraded…

PNC

PNC Financial

$133.52

0.09 (0.07%)

GS

Goldman Sachs

$230.26

-0.77 (-0.33%)

WFC

Wells Fargo

$54.03

-0.22 (-0.41%)

MS

Morgan Stanley

$47.74

-0.48 (-1.00%)

JPM

JPMorgan

$94.12

-0.71 (-0.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 03

    Oct

  • 12

    Oct

  • 13

    Oct

  • 13

    Oct

  • 17

    Oct

  • 22

    Oct

  • 29

    Nov

  • 15

    Jan

  • 27

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

JPM

JPMorgan

$94.12

-0.71 (-0.75%)

05:01
09/26/17
09/26
05:01
09/26/17
05:01
Downgrade
JPMorgan rating change  »

JPMorgan downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 12

    Oct

  • 22

    Oct

  • 27

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

JWN

Nordstrom

$47.32

0.44 (0.94%)

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
Nordstrom management to meet with Wolfe Research »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

BMY

Bristol-Myers

$63.19

-0.17 (-0.27%)

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
Bristol-Myers management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

  • 18

    Oct

  • 26

    Oct

  • 08

    Nov

  • 09

    Nov

  • 05

    Mar

MCO

Moody's

$138.78

0.75 (0.54%)

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
Moody's management to meet with Piper Jaffray »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 26

    Sep

ALB

Albemarle

$128.89

-5.4 (-4.02%)

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
Albemarle management to meet with Seaport Global »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

AFSI

AmTrust

$12.98

-0.3 (-2.26%)

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
AmTrust management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

NEE

NextEra Energy

$146.82

0.46 (0.31%)

, AES

AES Corp.

$11.21

0.1 (0.90%)

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
Wolfe Research to hold a conference »

Utilities & Power…

NEE

NextEra Energy

$146.82

0.46 (0.31%)

AES

AES Corp.

$11.21

0.1 (0.90%)

PEGI

Pattern Energy

$25.53

-0.37 (-1.43%)

LNT

Alliant Energy

$42.25

0.52 (1.25%)

AGR

Avangrid

$47.10

0.6 (1.29%)

PNW

Pinnacle West

$86.85

0.7 (0.81%)

ETR

Entergy

$77.76

1.01 (1.32%)

PEG

PSEG

$46.50

0.31 (0.67%)

AWK

American Water

$82.48

0.45 (0.55%)

CMS

CMS Energy

$47.10

0.63 (1.36%)

AEP

American Electric

$71.04

0.47 (0.67%)

D

Dominion

$78.02

0.98 (1.27%)

ED

Consolidated Edison

$82.24

0.65 (0.80%)

ES

Eversource

$61.47

0.76 (1.25%)

EIX

Edison International

$79.27

0.99 (1.26%)

DUK

Duke Energy

$85.14

0.89 (1.06%)

DTE

DTE Energy

$109.74

1.36 (1.25%)

FE

FirstEnergy

$31.11

0.22 (0.71%)

WEC

WEC Energy

$64.24

0.63 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 02

    Oct

  • 02

    Oct

  • 05

    Nov

  • 29

    Nov

DNOW

NOW Inc.

$13.26

0.27 (2.08%)

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
NOW Inc. management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

  • 01

    Nov

ALGT

Allegiant Travel

$133.95

3.85 (2.96%)

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
Allegiant Travel management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

XPER

Xperi

$24.70

-0.35 (-1.40%)

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
Xperi management to meet with Craig Hallum »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

OZRK

Bank of the Ozarks

$45.90

0.34 (0.75%)

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
Bank of the Ozarks management to meet with Piper Jaffray »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

  • 28

    Sep

  • 29

    Sep

04:55
09/26/17
09/26
04:55
09/26/17
04:55
General news
Consumer Confidence to be reported at 10:00 »

September Consumer…

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
Citigroup to hold a forum »

Pan Asia Corporate Forum…

BGG

Briggs & Stratton

$22.93

0.24 (1.06%)

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
Briggs & Stratton management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

PLUS

ePlus

$87.95

-0.65 (-0.73%)

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
ePlus management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

04:55
09/26/17
09/26
04:55
09/26/17
04:55
General news
Breaking General news story  »

Federal Reserve Chair…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.